2. Anti-infection
  3. Virus Protease Flavivirus
  4. IRBM-Z-2

IRBM-Z-2 is a non-competitive, orally active Zika virus (ZIKV) NS2B-NS3 protease inhibitor, with IC50 values of 0.04 μM and 3.1 μM against the wild-type and I156T mutant strains, respectively. IRBM-Z-2 exhibits broad-spectrum anti-flavivirus potential, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-1 inhibits ZIKV replication and alleviates virus-induced cytopathic effects. IRBM-Z-1 can be used in studies related to ZIKV infection.

For research use only. We do not sell to patients.

IRBM-Z-2

IRBM-Z-2 Chemical Structure

CAS No. : 3014840-61-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IRBM-Z-2 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IRBM-Z-2 is a non-competitive, orally active Zika virus (ZIKV) NS2B-NS3 protease inhibitor, with IC50 values of 0.04 μM and 3.1 μM against the wild-type and I156T mutant strains, respectively. IRBM-Z-2 exhibits broad-spectrum anti-flavivirus potential, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-1 inhibits ZIKV replication and alleviates virus-induced cytopathic effects. IRBM-Z-1 can be used in studies related to ZIKV infection[1].

In Vitro

In biochemical assays, IRBM-Z-2 inhibits the activity of the DENV2 NS2B-NS3T156I mutant protease with an IC50 of 0.4 μM, exhibiting stronger potency compared to the wild-type protease[1].
IRBM-Z-2 (72 h) potently inhibits the replication of wild-type Zika virus (ZIKV) replicons in Vero cells, with an EC50 of 0.03 μM, and no cytotoxicity is detected at concentrations up to 32 μM[1].
IRBM-Z-2 (72 h) inhibits the replication of ZIKV I156T mutant replicon in Vero cells, with an EC50 of 0.79 μM. No cytotoxicity is detected at concentrations up to 32 μM, and it exhibits a characteristic of reduced potency compared with the wild-type replicon[1].
IRBM-Z-2 (72 h) inhibits the replication of WNV replicons in Vero cells with an EC50 of 0.31 μM, and no cytotoxicity is detected at concentrations up to 32 μM[1].
IRBM-Z-2 (6 days) potently inhibits the cytopathic effect (CPE) induced by the ZIKV PRVABC59 strain in BHK-21 cells, with an EC50 of 0.016 μM, and no cytotoxicity is detected even at a concentration as high as 37.9 μM[1].
IRBM-Z-2 (48 h) inhibits the ZIKV Padova strain and H/PF/2013 strain in HuH-7 cells, with apparent IC50 values ranging from 6 to 20 nM, and no cytotoxicity is detected at the tested concentrations[1].
IRBM-Z-2 (6 days) inhibits the cytopathic effect (CPE) induced by West Nile virus strain Kern 515 in Vero76 cells, with an EC50 of 1.0 μM, and no cytotoxicity is detected at concentrations up to 50 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IRBM-Z-2 Related Antibodies
Parmacokinetics
Species Dose Route CL Vdss T1/2 Plasma Concentration Cmax AUC Bioavailability
Rat[1] 1 mg/kg i.v. 6.1 mL/min/kg 0.8 L/kg 2.3 h / / / /
Rat[1] 3 mg/kg p.o. / / / / 1.4 μM 5.0 μM·h 29 %
Rat[1] 1 mg/kg i.v. 9.7 mL/min/kg 1.4 L/kg 2.8 h / / / /
Rat[1] 3 mg/kg p.o. / / / / 1.6 μM 4.0 μM·h 90 %
Rat[1] 100 mg/kg i.p. / / / >1.39 μM / / /
Rat[1] 100 mg/kg p.o. / / / >1.39 μM 23.3 μM 208 μM·h /
In Vivo

IRBM-Z-2 (100 mg/kg; intraperitoneally; once daily; 5 consecutive days) reduces ZIKV serum viral load by up to 4.5 log10 and fully prevents ZIKV-induced weight loss in AG129 mice[1].
IRBM-Z-2 (100 mg/kg; oral gavage; twice daily; 14 consecutive days) reduces ZIKV serum viral load to undetectable levels by day 5, prevents ZIKV-induced weight loss, and results in 100% survival of AG129 mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: AG129 (male, 5 weeks old, IFNα/β and IFNγ receptors deficient)[1]
Dosage: 100 mg/kg
Administration: intraperitoneally; once daily; 5 consecutive days
Result: Reduced serum viral RNA levels by 3.6 log10 compared to untreated controls by day 1.
Reduced serum viral RNA levels by 4.5 log10 compared to untreated controls by the end of the 5-day study.
Fully protected mice from ZIKV-induced weight loss.
Showed no adverse clinical signs.
Animal Model: AG129 (male, 5 weeks old, IFNα/β and IFNγ receptors deficient)[1]
Dosage: 100 mg/kg
Administration: oral gavage; twice daily; 14 consecutive days
Result: Reduced serum viral RNA levels by more than 6 log10 compared to vehicle-treated controls by day 3 post-infection.
Reduced serum viral RNA levels below the limit of detection by day 5, remaining undetectable through the end of the 14-day study.
Prevented ZIKV-induced weight loss.
Showed no adverse clinical signs.
Achieved 100% survival of treated mice over 14 days, compared to full mortality of vehicle controls by day 9.
Molecular Weight

469.42

Formula

C22H18F3N7O2
CAS No.
SMILES

O=C(NC1=CC=CC(C(F)(F)F)=C1)[N-]C2=C[N+](CC3=CC=C(C4=C(C)N=CN=C4C)C=N3)=NO2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IRBM-Z-2 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IRBM-Z-23014840-61-7Virus ProteaseFlavivirusBHK-21 cellsVero cellsI156T mutantAG129 mouse modelsVero76 cellsWest Nile virus NS2B-NS3 proteaseDengue virus type 2 NS2B-NS3 proteaseHuH-7 cellsZika virus NS2B-NS3 proteasemiceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IRBM-Z-2
Cat. No.:
HY-181991
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.